We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+27.45%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$855M
AUM Growth
-$72.2M
Cap. Flow
+$34.1M
Cap. Flow %
3.99%
Top 10 Hldgs %
52.05%
Holding
72
New
17
Increased
11
Reduced
9
Closed
25

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$34.2M
2
INSM icon
Insmed
INSM
+$32.4M
3
CYTK icon
Cytokinetics
CYTK
+$26M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$25.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.7M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$42.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$30.6M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$30M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$23M
5
IMVT icon
Immunovant
IMVT
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
1
IDEAYA Biosciences
IDYA
$3.76B
$77.1M 9.02%
3,000,000
+900,000
+43% +$25.5M
JANX icon
2
Janux Therapeutics
JANX
$1.03B
$66.9M 7.83%
1,250,000
+250,000
+25% +$13.2M
RVMD icon
3
Revolution Medicines
RVMD
$41.9B
$63.4M 7.42%
1,450,000
+250,000
+21% +$12.6M
CYTK icon
4
Cytokinetics
CYTK
$9.73B
$42.3M 4.95%
900,000
+500,000
+125% +$26M
VERA icon
5
Vera Therapeutics
VERA
$2.48B
$37M 4.33%
875,000
+375,000
+75% +$16.6M
BNTX icon
6
BioNTech
BNTX
$24.8B
$34.2M 4%
+300,000
New +$34.2M
MRUS
7
DELISTED
Merus
MRUS
$31.5M 3.69%
750,000
+175,000
+30% +$8.4M
ERAS icon
8
Erasca
ERAS
$5.33B
$31.4M 3.67%
12,500,000
+1,600,000
+15% +$4.39M
INSM icon
9
Insmed
INSM
$26.9B
$31.1M 3.64%
+450,000
New +$32.4M
OCUL icon
10
Ocular Therapeutix
OCUL
$2.23B
$29.9M 3.5%
3,500,000
– –
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.4B
$27.3M 3.19%
+200,000
New +$24.7M
DSGN icon
12
Design Therapeutics
DSGN
$805M
$26M 3.04%
4,217,627
– –
PCVX icon
13
Vaxcyte
PCVX
$9.02B
$24.6M 2.87%
300,000
– –
AKRO
14
DELISTED
Akero Therapeutics
AKRO
$22.3M 2.6%
800,000
– –
JAZZ icon
15
Jazz Pharmaceuticals
JAZZ
$15.9B
$21.6M 2.52%
+175,000
New +$20.6M
GPCR icon
16
Structure Therapeutics
GPCR
$2.53B
$19M 2.22%
700,000
-550,000
-44% -$19.5M
OLMA icon
17
Olema Pharmaceuticals
OLMA
$864M
$18.7M 2.19%
3,208,875
– –
BPMC
18
DELISTED
Blueprint Medicines
BPMC
$17.4M 2.04%
+200,000
New +$18.3M
TVTX icon
19
Travere Therapeutics
TVTX
$6.09B
$17.4M 2.04%
1,000,000
-100,000
-9% -$1.77M
APLS
20
DELISTED
Apellis Pharmaceuticals
APLS
$16M 1.87%
+500,000
New +$15M
SLNO
21
DELISTED
Soleno Therapeutics
SLNO
$15.7M 1.84%
+350,000
New +$18.1M
ALKS icon
22
Alkermes
ALKS
$7.83B
$14.4M 1.68%
+500,000
New +$14.4M
APGE
23
DELISTED
Apogee Therapeutics
APGE
$13.6M 1.59%
+300,000
New +$15.3M
ARVN icon
24
Arvinas
ARVN
$543M
$13.4M 1.57%
700,000
+300,000
+75% +$7.29M
ANNX icon
25
Annexon
ANNX
$787M
$13.1M 1.53%
2,550,000
-50,000
-2% -$308K
1
2 3

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q4 2024 Portfolio in Review

As of Q4 2024, Logos Global Management held 72 positions worth $855M, down 7.8% from $927M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Logos Global Management deployed $34.1M of net new capital in Q4 2024, opening 17 new positions and adding to 11 existing holdings. Its largest new stake was BioNTech: 300,000 shares worth $34.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Disc Medicine, an estimated $42.5M trimmed.

  • Logos Global Management's largest Q4 2024 buy was BioNTech: 300,000 shares worth $34.2M.
  • Logos Global Management added most to Cytokinetics in Q4 2024, an estimated $26M increase.
  • Logos Global Management's biggest Q4 2024 reduction was Disc Medicine, cutting an estimated $42.5M.
  • Logos Global Management fully exited Celldex Therapeutics in Q4 2024, selling an estimated $30.6M.
  • Logos Global Management's ten largest holdings make up 52% of its $855M portfolio in Q4 2024.
  • Logos Global Management opened 17 new positions and closed 25 in Q4 2024.
  • Logos Global Management's portfolio value fell 7.8% quarter-over-quarter to $855M.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.